2. Academic Validation
  3. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity

Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity

  • Nat Nanotechnol. 2023 Dec 5. doi: 10.1038/s41565-023-01553-6.
Guangna Liu # 1,  Nana Ma # 1,  Keman Cheng # 1,  Qingqing Feng 1,  Xiaotu Ma 1,  Yale Yue 1,  Yao Li 1,  Tianjiao Zhang 1,  Xiaoyu Gao 1,  Jie Liang 1,  Lizhuo Zhang 1,  Xinwei Wang 1,  Zhenhua Ren 2,  Yang-Xin Fu 2 3,  Xiao Zhao 4 5 6,  Guangjun Nie 7 8
Affiliations

Affiliations

  • 1 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China.
  • 2 Changping Laboratory, Beijing, China.
  • 3 Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
  • 4 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China. [email protected].
  • 5 Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, China. [email protected].
  • 6 IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China. [email protected].
  • 7 CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China. [email protected].
  • 8 Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, China. [email protected].
  • # Contributed equally.
PMID: 38052943 DOI: 10.1038/s41565-023-01553-6
Abstract

Trained immunity enhances the responsiveness of immune cells to subsequent infections or vaccinations. Here we demonstrate that pre-vaccination with bacteria-derived outer-membrane vesicles, which contain large amounts of pathogen-associated molecular patterns, can be used to potentiate, and enhance, tumour vaccination by trained immunity. Intraperitoneal administration of these outer-membrane vesicles to mice activates inflammasome signalling pathways and induces interleukin-1β secretion. The elevated interleukin-1β increases the generation of antigen-presenting cell progenitors. This results in increased immune response when tumour antigens are delivered, and increases tumour-antigen-specific T-cell activation. This trained immunity increased protection from tumour challenge in two distinct Cancer models.

Figures
Products